Skip to main content
Future Journal of Pharmaceutical Sciences
Fig. 1 | Future Journal of Pharmaceutical Sciences

Fig. 1

From: Metformin and asarone inhibit HepG2 cell proliferation in a high glucose environment by regulating AMPK and Akt signaling pathway

Fig. 1

Metformin and asarone inhibit the growth and modify the morphology of HepG2 cells. A–C Cells were treated with metformin HCl, α-asarone, and β-asarone as indicated for 48 h and the cell viability was determined by MTT assay. D Representative images to show the morphology of HepG2 cells under an inverted microscope. The scale of the bar is 100 μm. a Untreated group; the morphology of HepG2 cells had a high density with adherent cell colonies, whereas, in the treatment group, metformin HCl (b) and asarone (c, d) at higher concentration showed lower density with a small round body. Values represent mean ± SEM of an experiment done in triplicate; one-way ANOVA followed by Bonferroni test, where *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the untreated (UT) group

Back to article page